Skip to main content
. Author manuscript; available in PMC: 2017 Jun 1.
Published in final edited form as: Neurobiol Aging. 2016 Mar 2;42:50–60. doi: 10.1016/j.neurobiolaging.2016.02.025

Figure 4. Meox2 haploinsufficency does not alter glial activation in B6.APBTg.Mx−/+ mice.

Figure 4

(A) Representative images of GFAP immunostaining of astrocytes in the cortex of B6, B6.APBTg, B6.Mx−/+, and B6.APBTg.Mx−/+ mice at 14 months of age. (B) Representative images of IBA1 immunostaining of microglial cells in the cortex of B6, B6.APBTg, B6.Mx−/+, and B6.APBTg.Mx−/+ mice at 14 months of age. (C) Quantitative analysis of GFAP-immunolabeled area in the cortex of B6, B6.APBTg, B6.Mx−/+, and B6.APBTg.Mx−/+ mice at 10 and 14 months of age. Significant increases in GFAP levels were observed B6.APBTg and B6.APBTg.Mx−/+ mice compared to B6 or B6.Mx−/+ mice. No significant differences were observed between B6.APBTg and B6.APBTg.Mx−/+mice. (D) Quantitative analysis of IBA1+ microglial cells in the cortex of B6, B6.APBTg, B6.Mx−/+, and B6.APBTg.Mx−/+ mice at 10 and 14 months of age. Significant increases in IBA1+ cells were observed B6.APBTg and B6.APBTg.Mx−/+ mice compared to B6 or B6.Mx−/+ mice. No significant differences were observed between B6.APBTg and B6.APBTg.Mx−/+ mice. In (C-D) values are mean ± SEM, n= 4 mice per group, **P< 0.01, ***P< 0.001,and ****P< 0.0001 by one-way ANOVA. Scale bars: 50μm